8-K: Avalo Therapeutics Reports Strong Cash, HS Trial Progress

Avalo Therapeutics, Inc. announced an estimated $98 million in cash, cash equivalents, and short-term investments as of December 31, 2025, providing a cash runway into 2028, alongside completed enrollment for its Phase 2 LOTUS trial in hidradenitis suppurativa.

Summary

• Estimated cash, cash equivalents, and short-term investments of approximately $98 million as of December 31, 2025.
• This cash position is expected to provide a cash runway into 2028.
• Enrollment for the Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS) is complete.
• Topline data from the Phase 2 LOTUS trial is expected in Q2 2026.
• AVTX-009 is a high-affinity, IL-1 specific monoclonal antibody designed to treat immune-mediated inflammatory diseases, with HS as its lead indication.
• The HS market is projected to grow to over $10 billion by 2035.
• The company's adjusted common shares outstanding are 37.3 million, leading to an adjusted market capitalization of $677.5 million based on a stock price of $18.16 as of December 31, 2025.

Sentiment

Score: 7

Explanation: The filing presents a positive outlook with a strong cash position, significant progress in a key clinical trial, and a large addressable market. However, the financial data is preliminary, and clinical trial success is not guaranteed, introducing some uncertainty.

Positives

• Strong estimated cash position of $98 million as of December 31, 2025, providing an expected cash runway into 2028.
• Enrollment for the pivotal Phase 2 LOTUS trial in hidradenitis suppurativa (HS) is complete, a significant clinical development milestone.
• Topline data for the Phase 2 LOTUS trial is anticipated in Q2 2026, offering a clear near-term catalyst.
• AVTX-009, the lead compound, is an IL-1 specific mAb with potential for a best-in-class and best-in-disease profile in HS due to higher affinity and longer half-life compared to lutikizumab.
• The hidradenitis suppurativa market is projected to grow substantially to over $10 billion by 2035, indicating a large potential market for AVTX-009.
• The company has a proven management team with over 220 years of combined experience in biotech/pharma.
• Broad potential for indication expansion for AVTX-009 into other IL-1 driven diseases like arthritis and inflammatory bowel disease.

Negatives

• The financial information provided (cash, cash equivalents, short-term investments) is unaudited and preliminary, subject to material change in the Annual Report on Form 10-K.
• The efficacy and safety of AVTX-009 are still under investigation, with topline Phase 2 data not expected until Q2 2026.
• The company operates in a highly competitive therapeutic area with existing market leaders and pipeline therapeutics.

Risks

• Drug development costs, timing of trial results, and other risks, including reliance on investigators and enrollment of patients in clinical trials.
• Reliance on key personnel.
• Regulatory risks.
• General economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East.
• Actual financial results for the year ended December 31, 2025, may differ materially from the preliminary estimate.

Future Outlook

The company expects its current cash, cash equivalents, and short-term investments to fund operations into 2028. Topline data from the Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa is anticipated in Q2 2026, with plans to initiate a pivotal program in 2027, pending positive Phase 2 results. The hidradenitis suppurativa market is projected to exceed $10 billion by 2035, driven by increased diagnosis and treatment.

Management Comments

• Our mission is advancing an inspired pipeline of novel IL-1 therapies focused on treating unmet medical needs.
• Avalo Therapeutics is advancing the next-generation of IL-1 inhibition for immune-mediated inflammatory diseases.
• AVTX-009 has the potential for best-in-class and best-in-disease profile in hidradenitis suppurativa (HS).
• Avalo is currently assessing additional immunology indications for investment.

Industry Context

The announcement positions Avalo Therapeutics within the competitive landscape of immune-mediated inflammatory diseases, specifically targeting hidradenitis suppurativa (HS). The HS market is characterized by significant unmet needs due to incomplete response and loss of response to current anti-TNF and anti-IL-17 treatments. Avalo's AVTX-009, an IL-1 specific mAb, aims to differentiate itself by targeting a key immunoregulator in HS, IL-1, which is upstream of IL-17 and TNF. The projected growth of the HS market to over $10 billion by 2035 underscores the commercial potential for effective new therapies in this space, driven by increased diagnosis and treatment rates.

Comparison to Industry Standards

• AVTX-009 (anti-IL-1 mAb) is compared to AbbVie's lutikizumab (IL-1α/β), with AVTX-009 having higher affinity and a longer half-life, potentially predictive of higher efficacy and less frequent dosing.
• Lutikizumab demonstrated favorable Phase 2 efficacy in a refractory HS population that had failed anti-TNF therapy, suggesting a role for IL-1 inhibition.
• Bermekimab, an IL-1α specific mAb, performed no better than placebo in a Phase 2 study with an adalimumab comparator arm, highlighting the importance of IL-1β specificity.
• Current treatments for HS, including anti-TNF and anti-IL-17 biologic therapies (e.g., Humira, Cosentyx), often result in significant and life-disrupting symptoms for a large proportion of patients due to limited efficacy.
• The company notes that IL-1 targeting therapies are approved in other arthritis indications (e.g., RA, acute gout flare with Ilaris, Kineret) and rare autoinflammatory diseases (e.g., periodic fevers, DIRA, Stills disease, recurrent pericarditis with Arcalyst), providing established clinical proof of concept for the IL-1 pathway.
• The CANTOS study (Novartis) with canakinumab (IL-1β blockage) reduced total joint replacements in OA patients with high CRP and major CV events in patients with prior MI and elevated CRP, further supporting the broad potential of IL-1 inhibition.

Stakeholder Impact

• Shareholders: Potential for increased value if AVTX-009's Phase 2 trial is successful and the company maintains its strong financial position. Preliminary financial data introduces some uncertainty.
• Patients (with HS and other immune-mediated inflammatory diseases): Potential for a new, more effective treatment option (AVTX-009) to address significant unmet needs.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline.

Next Steps

• Topline data readout for the Phase 2 LOTUS trial in Q2 2026.
• Initiate pivotal program for AVTX-009 in 2027, pending Phase 2 readout.
• Assess additional immunology indications for investment.
• Include actual results for the year ended December 31, 2025, in the Annual Report on Form 10-K.

Key Dates

Recommendation

The company has a solid cash runway into 2028 and has achieved a significant milestone with the completion of enrollment for its Phase 2 LOTUS trial. The potential market for AVTX-009 in hidradenitis suppurativa is substantial. However, the preliminary nature of the financial data and the upcoming Q2 2026 topline data readout for the Phase 2 trial represent key uncertainties. While the long-term outlook is promising, a 'hold' recommendation is appropriate until more definitive clinical results are available, as the stock's performance will likely be highly sensitive to these outcomes.

Keywords

Avalo Therapeutics, AVTX, Hidradenitis Suppurativa, HS, IL-1 inhibition, AVTX-009, Phase 2 LOTUS trial, Biotechnology, Pharmaceuticals, Immunology, Inflammatory diseases, Cash runway, Clinical trial data